Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with standard of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.
Read More
Provista’s proprietary ProteoMark® Technology combines multiple Serum Protein Biomarkers and Tumor Associated Autoantibodies, with patient clinical data, to yield highly accurate diagnostic tests for women’s cancers.
Read More
Provista is developing a robust pipeline of diagnostic blood tests to address unmet needs in women’s cancers including breast, ovarian, endometrial and HPV-associated cancers.
Read More
Diagnostic Dilemma
Dense breast tissue is normal and common among woman and it refers to the appearance of breast tissue on a mammogram. Dense tissue appears white on a mammogram similar to both benign and cancerous lumps leading to both false negative and false positive results.
Read More


Sign Up for E-News
July 7, 2016

Jul 7, 2016

Breast Cancer Blood Test Now Accessible Under Health Benefits for Millions of Women in the U.S. Provista Diagnostics Announces 13 Signed Agreements with Third Party Administrator Networks New York – July 7, 2016 – Provista Diagnostics, a private company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers […]
June 2, 2016

Jun 2, 2016

Provista Diagnostics Announces Positive Trial Results Assessing the Use of Videssa® Breast to Detect Breast Cancer Findings from Trial’s Second Cohort Replicate Prior Results New York – June 2, 2016 – Provista Diagnostics, a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced […]
May 25, 2016

May 24, 2016

Provista Diagnostics to Present at The 2016 BIO International Convention NEW YORK, NY – May 24, 2016 – Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the 2016 BIO International Convention,taking place June 6-9, 2016 at the Moscone […]